PUBLIC RELEASE DATE: <\/p>\n
3-Dec-2014 <\/p>\n
Contact: Kathryn Ryan kryan@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News @LiebertOnline<\/p>\n New Rochelle, NY, December 3, 2014--Hereditary angioedema (HAE), a rare genetic disease that causes recurrent swelling under the skin and of the mucosal lining of the gastrointestinal tract and upper airway, usually first appears before 20 years of age. A comprehensive review of the therapies currently available to treat HAE in adults shows that some of these treatments are also safe and effective for use in older children and adolescents. Current and potential future therapies are discussed in a Review article in a special issue of Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Pediatric Allergy, Immunology, and Pulmonology website at http:\/\/online.liebertpub.com\/doi\/full\/10.1089\/ped.2014.0412<\/a> until January 3, 2015. <\/p>\n Based on the current medical literature, Eveline Wu, University of North Carolina at Chapel Hill, and Michael Frank, Duke University Medical Center (Durham, NC), report that additional therapies are now approved for use in the pediatric age group. In their article \"Management of Hereditary Angioedema in Childhood: A Review\" they also discuss clinical trials and published experience among younger age groups for which data are most limited. <\/p>\n \"HAE is a potentially life-threatening disease that until recently had very limited therapeutic options for children,\" says Pediatric Allergy, Immunology, and Pulmonology Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook (Stony Brook, NY). \"This special issue of Pediatric Allergy, Immunology, and Pulmonology, developed in collaboration with Guest Editor Dr. Timothy Craig, has been created for physicians who care for children. It focuses on recent advances in HAE-related immunophysiology, as well as current and future therapies for acute and chronic care and prophylaxis.\" <\/p>\n ### <\/p>\n About the Journal <\/p>\n Pediatric Allergy, Immunology, and Pulmonology is a quarterly, peer-reviewed journal published in print and online. The Journal synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. The Journal provides comprehensive coverage to further the understanding and optimize the treatment of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website at http:\/\/www.liebertpub.com\/ped<\/a>. <\/p>\n About the Publisher <\/p>\n <\/p>\n More here: PUBLIC RELEASE DATE: 3-Dec-2014 Contact: Kathryn Ryan kryan@liebertpub.com<\/a> 914-740-2100 Mary Ann Liebert, Inc.\/Genetic Engineering News @LiebertOnline New Rochelle, NY, December 3, 2014--Hereditary angioedema (HAE), a rare genetic disease that causes recurrent swelling under the skin and of the mucosal lining of the gastrointestinal tract and upper airway, usually first appears before 20 years of age. A comprehensive review of the therapies currently available to treat HAE in adults shows that some of these treatments are also safe and effective for use in older children and adolescents. Current and potential future therapies are discussed in a Review article in a special issue of Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers Continue reading
\nAre there safe and effective treatments for hereditary angioedema in children?<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"